If you’ve ever looked at a protein diagram and thought, “Cool, but also… is that spaghetti?” you’re not alone.
Proteins are the squiggles that run your life: they move oxygen, digest food, build muscle, andif you let themcan help
manufacture cleaner chemicals, smarter materials, and more sustainable products. The twist in 2025 is that we’re not just
studying proteins anymore. We’re engineering them like custom parts. And the U.S. National Science Foundation (NSF)
just put serious fuel in that tank.

The NSF Directorate for Technology, Innovation and Partnerships (TIP) announced an inaugural investment of nearly
$32 million through the NSF Use-Inspired Acceleration of Protein Design (USPRD) initiativesupporting five
cross-sector teams across the United States. The mission: push AI-enabled protein design out of “wow, neat demo” territory
and into practical, market-ready solutions that matter for the U.S. bioeconomy.

What NSF TIP Actually Announced (And Why It’s A Big Deal)

Here’s the headline in plain English: NSF TIP is backing five teams to accelerate AI-driven protein designespecially
enzyme designso the technology becomes easier to use, cheaper to validate, and more reliable in real-world conditions.
Think of it as a national effort to turn protein design from “artisan craft” into “scalable manufacturing capability.”

This matters because protein design sits at the crossroads of multiple national priorities at once: domestic manufacturing,
resilient supply chains, climate and sustainability, advanced materials, and biotech leadership. When enzymes can replace
harsh chemical steps, industries can potentially cut energy use, reduce toxic byproducts, and make processes more flexible.
When proteins can be designed on demand, innovation cycles shrink from “years of trial-and-error” to “iterate, test, and ship”
at modern speed.

Meet NSF TIP: The Directorate Built for “So What?” Moments

TIP is NSF’s directorate focused on use-inspired and translational researchwork that still has scientific teeth, but also has
a plan for how it becomes jobs, products, and impact. TIP’s mission centers on accelerating critical and emerging technologies,
expanding the geography of American innovation, and building a competition-ready workforce. In other words: not just great papers,
but great outcomes.

TIP was formally codified in the “CHIPS and Science Act of 2022,” which also authorized major funding for TIP initiatives over
FY 2023–2027. That context matters: USPRD isn’t a random one-off. It fits into a national strategy to translate U.S. science
into economic strengthespecially in technologies that define competitiveness.

USPRD 101: “Use-Inspired Acceleration of Protein Design” Without the Jargon

USPRD stands for Use-Inspired Acceleration of Protein Design. The key phrase is “use-inspired.”
This initiative isn’t only about designing proteins that look good in simulation. It’s about designing proteins that do something
usefulat scaleunder messy real-world constraints (cost, stability, manufacturability, regulation, supply chains, and customers
who absolutely will ask, “Can we make 10,000 units by next quarter?”).

USPRD also emphasizes breakthroughs beyond therapeutics. Yes, proteins matter in medicine, but USPRD explicitly targets broader
applications like advanced materials, biomanufacturing, agriculture and food security, environmental remediation, sustainability,
and climate-related challenges. In other words: proteins for the entire economy, not just the pharmacy aisle.

The Ideas Lab Approach: When Funding Starts With Collaboration

USPRD used an “Ideas Lab” processa structured, intensive workshop model designed to bring experts and stakeholders together to
co-develop aggressive but attainable solutions to a defined challenge. It’s less “submit your proposal into the void” and more
“lock smart people in a room (with snacks) until a better plan emerges.”

The USPRD funding opportunity outlined two tracks: one focused on use-driven applications for small binders, and another focused on
designing enzymes and families of enzymes. That enzyme emphasis is crucial, because enzymes are the workhorses of industrial biology:
they catalyze reactions that can convert renewable feedstocks into fuels, materials, and specialty chemicals.

Why Protein Design Is Suddenly Everywhere (And Not Just In Sci-Fi)

The protein design boom didn’t come out of nowhere. Several trends collided:
better structural biology, massive public datasets, cheaper compute, and deep learning methods that can learn patterns
across sequences and structures.

One foundational ingredient is shared data infrastructure. Protein structure repositories like the Protein Data Bank (PDB) have grown
into massive open resources that power research, machine learning, and design workflows. That matters because AI is only as good as the
data ecosystem it learns from.

On the methods side, protein design has seen rapid progress in deep learning approaches that can propose sequences and structures
with functional intentmoving from “predict what nature did” toward “engineer what we want.” The results are increasingly practical:
designed binders, enzymes, and functional sites that can be experimentally validated and tuned.

Add in the broader cultural momentwhere AI breakthroughs in biology are being recognized at the highest levelsand you get a field
that’s both scientifically hot and economically consequential. TIP is essentially betting that the U.S. should industrialize this capability,
not just admire it.

The Five USPRD Awards: What They’re Building (And What It Could Enable)

NSF’s USPRD investment supports five teams spanning industry and academia. Each is aimed at a concrete bottleneck:
producing important molecules more efficiently, boosting biomanufacturing performance, enabling new nutrition products,
and turning biomass into valuable goods. Here’s what’s on the menu.

1) Arzeda Corp. AI-Designed Enzymes for Bio-Based Acrylates

Acrylates show up in everyday products like paints, Plexiglas-type materials, and super-absorbent polymers. They’re useful,
but producing them can be expensive and resource-intensive. Arzeda’s USPRD project targets enzyme engineering to create
scalable, cost-effective biocatalytic routes to acrylatesleveraging AI and protein engineering, including strategies involving
cofactor analogs for stability and performance.

Why this matters: if you can make a common industrial building block through cleaner biocatalysis, it’s not just “one product got greener.”
It’s a proof point that enzyme design can compete in heavyweight chemical marketswhere margins are tight and scale is unforgiving.

2) Koliber Biosciences Inc. “Transporters With Transformers”

Biomanufacturing often runs into an unglamorous constraint: moving small molecules across cell membranes. If inputs can’t get in
efficientlyor products can’t get outyour microbial factory becomes a traffic jam with feelings.

Koliber’s project aims to develop AI/ML tools to select and optimize transporters, improving the throughput and efficiency of microbial
production systems. The potential payoff is broad: lower costs and more resilient domestic production for chemicals used across food,
agriculture, energy, and industrial supply chains.

3) Novozymes Inc. Cell-Free Synthesis of Longer Human Milk Oligosaccharides (HMOs)

Human milk oligosaccharides (HMOs) are complex nutrients linked to infant health and development, but they can be difficult to produce,
especially longer, more biologically relevant forms. This project aims to engineer enzymes and optimize a cell-free protein synthesis approach,
using machine learning and advanced enzyme engineering to expand what’s manufacturable.

Translation angle: this isn’t just “cool biochemistry.” It’s a path toward improved infant nutrition products and a broader enzyme toolkit
with commercial properties useful in human health and nutrition.

4) Purdue University Programmable Small Molecule Biosynthesis

Not all plastics are born equal. Some are recyclable, some are biodegradable, and some are basically immortal. Purdue’s project targets the
design of microbial systems that can efficiently produce biodegradable and recyclable plastics that can withstand high temperaturesan attempt
to create high-performance materials without the “oops, we polluted the planet for 300 years” side quest.

If successful, it could strengthen domestic manufacturing of sustainable materials and expand the practical reach of biodesign into advanced materials.

5) UC Santa Barbara Enzymes for Biomass Upcycling to Surfactants and Fuels

Biomass upcycling is the art of turning plant material into valuable products like fuels, lubricants, and surfactants. The bottleneck is often enzymes:
they need to be robust, selective, and efficient with messy real-world feedstocks.

UCSB’s project leverages AI-based methods to design and evolve enzymes that can make biomass conversion more scalable and cost-effectivesupporting
sustainable biomanufacturing and expanding the economic potential of the bioeconomy.

The Strategic Logic: Why These Awards Are More Than “Five Cool Projects”

A common thread across the five awards is not merely “protein design is neat.” It’s that protein design is becoming an enabling platform technology.
When platforms mature, they tend to create ripple effects: new tooling, standards, workforce skills, and partnerships that outlast any single project.

USPRD explicitly targets that platform-building layer. Beyond the use-driven work (the thing you can point to in a demo), the initiative emphasizes
infrastructure components (tools, datasets, characterization services), designer-facing components (so more people can actually use the tools), ecosystem
components (standards, roadmaps, open resources), and workforce components (training translational talent).

Put bluntly: it’s hard to build a “protein design economy” if only a handful of wizard labs can do it. USPRD is trying to widen the on-ramp.

How This Fits the Bigger U.S. Bioeconomy Push

The U.S. government has been explicit that biotechnology and biomanufacturing are central to national competitiveness. Executive actions and agency plans
in recent years have emphasized a whole-of-government approach to strengthening the American bioeconomycovering health, climate, energy, agriculture,
supply chain resilience, and national security.

In that environment, USPRD looks like a targeted move to ensure the U.S. doesn’t just discover breakthroughsit translates them. Protein design is one
of those “force multiplier” technologies: if you can design enzymes and proteins faster and more reliably, you can improve manufacturing routes, develop
new materials, and unlock products that were previously too expensive or too slow to produce.

What Success Might Look Like (Beyond Headlines and Ribbon Cuttings)

A realistic success metric for USPRD isn’t “one magical enzyme fixes everything.” It’s a portfolio of translation wins:
repeatable workflows, validated design-to-test pipelines, shared datasets and benchmarks, characterization services that reduce friction, and a workforce
that can operate at the intersection of AI and wet-lab biology.

• Faster iteration: fewer wet-lab cycles to reach functional performance targets.
• Better reliability: designed proteins that behave consistently in production conditions.
• Broader participation: more teams (including startups and universities beyond the usual hubs) able to contribute.
• Industrial adoption: proteins that make it into real processes, products, and supply chains.
• Workforce development: scientists and engineers trained to translate, not just publish.

Challenges Worth Taking Seriously (Because Proteins Don’t Care About Your PowerPoint)

Protein design is powerful, but it’s not effortless. Major challenges include: data quality and bias, generalization to new protein families,
modeling dynamics (especially for enzymes), scaling experimental validation, and navigating IP and open-science tradeoffs. If you’ve ever tried to run
a lab protocol that worked “perfectly” in one lab and mysteriously failed in another, you already understand the vibe.

There’s also a broader responsibility layer. As protein design becomes more accessible, the ecosystem must keep pace with research security, safe
development practices, and clear guidance on responsible use. Translation at speed is greattranslation at speed with guardrails is better.

Who Should Care (Hint: More People Than Just Biologists)

USPRD sits at the intersection of AI, biotech, materials, manufacturing, and workforce developmentso the “who should care” list is wide:

• Startups: protein design toolchains can create defensible product advantages and faster R&D cycles.
• Manufacturers: enzymes can reduce cost, energy use, and waste in chemical processes.
• Investors: this is infrastructure funding that can de-risk a new generation of bio-based products.
• Universities: cross-sector collaborations and translational training are becoming core, not optional.
• Workforce programs: demand is growing for talent fluent in both computation and bench science.

Conclusion: A $32M Signal That Protein Design Is Moving From “Cool” to “Core”

NSF TIP’s USPRD investments aren’t just a funding announcementthey’re a statement about industrial readiness.
The U.S. is treating AI-enabled protein design as a strategic technology for the bioeconomy, and USPRD is structured to push the field toward real-world
adoption: tools, infrastructure, standards, talent, and use-driven demonstrations that can survive outside the lab.

The five projectsspanning bio-based acrylates, membrane transport optimization, advanced nutrition ingredients, sustainable plastics, and biomass upcycling
are varied on purpose. They show the breadth of what protein design can touch when it’s treated as an enabling platform. And if this initiative succeeds,
the most important output might not be a single breakthrough protein. It might be a national capability: the ability to design, validate, and deploy proteins
as reliably as we design chips, materials, and software.

Field Notes: Experiences You’ll Recognize Around NSF TIP’s USPRD Investments (Extra Section)

Below are real-world-style experiences commonly reported by teams working at the boundary of AI protein design and translation. They’re intentionally
anonymized and representativebecause in this space, the patterns matter more than the names on the lab coats.

Experience #1: The “Model Looked Great… Until Biology Happened” Moment

Many teams start with impressive in-silico results: strong predicted binding, clean active-site geometry, beautiful confidence scores.
Then the first wet-lab validation arrives like an uninvited critic: low expression, poor solubility, or activity that disappears under real process
conditions. The lesson usually isn’t “AI failed.” It’s “the objective function was incomplete.” Teams learn to incorporate manufacturability constraints
earlystability, expression, tolerance to solvents, temperature robustnessso models aren’t optimizing for a protein that only works in a computational
utopia. Over time, the workflow shifts: fewer hero shots, more boring-but-reliable iteration, and a growing appreciation for characterization pipelines
that produce consistent feedback.

Experience #2: Cross-Sector Collaboration Is Amazing… After You Translate the Vocabulary

USPRD’s cross-sector setup pushes academia and industry to co-develop solutions, which is powerfuland occasionally hilarious. Academic teams may speak in
“novelty” and “mechanism,” while industry partners speak in “cost,” “throughput,” and “regulatory timelines.” Early meetings can feel like two groups describing
the same elephant from opposite ends. The breakthrough often comes when the collaboration defines shared milestones: measurable activity, stability thresholds,
a cost-per-gram target, a time-to-validate goal. Once everyone agrees what “good” looks like, technical creativity becomes aligned with real adoption.

Experience #3: Data Isn’t Just FuelIt’s Steering

Teams frequently discover that their biggest bottleneck isn’t computeit’s data coverage. If training data under-represents the enzyme families, cofactors,
substrates, or process conditions they care about, predictions become fragile. Successful groups treat data generation as a first-class R&D activity:
building assay pipelines, curating negative results, standardizing measurement protocols, and creating datasets that reflect real industrial constraints.
Over time, teams stop asking “How do we build a better model?” and start asking “How do we build a better feedback loop?” That shift is often where translation
accelerates.

Experience #4: The “Tooling Gap” Becomes a Competitive Advantage

A common experience in protein design is realizing that even when the science works, the tooling doesn’t scale. Scripts are brittle, pipelines break,
versions drift, and the one person who knows how everything fits together goes on vacation (or graduates). Teams that invest early in usable software,
documentation, and reproducible workflows tend to move faster laterand they become magnets for collaborators. This is exactly why USPRD emphasizes
designer-facing components and infrastructure: it’s hard to build an ecosystem when every lab has to reinvent the same glue code.

Experience #5: The Best “Win” Is When Someone Else Can Use What You Built

Translation success often arrives quietly: a partner lab adopts your characterization workflow; a startup uses your dataset to benchmark its own model;
an industrial collaborator plugs your designed enzyme into a pilot line and sees meaningful yield improvements. These wins don’t always make flashy headlines,
but they’re the signs that protein design is becoming an enabling platform. Teams involved in programs like USPRD often end up optimizing for this kind of
impactbecause if adoption spreads, the field grows faster than any single team can scale alone.